drugset / Trial / NCT00267384

N-acetylcysteine Protects From Aminoglycosides Induced Nephrotoxicity

NCT00267384

Phase 2/3 Completed Soroka University Medical Center
RandomizedParallel-groupDouble-blindTreatment

Summary

This randomized, double-blind, placebo-controlled clinical trial will be performed to assess the effect of N-acetylcysteine therapy on the incidence of nephrotoxicity among patients hospitalized with an infection and treated with aminoglycosides (AGs). Secondary goals of the study will be as follows: comparison of the mortality rates, and length of hospitalization among patients treated with N-acetylcysteine compared to the control group.

Timeline

Start
2006-03
Primary completion
2008-05
Completion
2008-09

Drugs

EvaluationDrugModalityDoseRoute
Subject N-acetylcysteine Small molecule Oral

Indications

No indication recorded.